Physician profile
Vinod Abraham
NPI 1457438350
$2,231.12
in general payments reported to CMS, 2019-2025
22 companies · $561 in 2025
The $561 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $287 · 2020: $329 · 2021: $349 · 2022: $147 · 2023: $306 · 2024: $252 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,119.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $653.86 | 2022-2025 | Qulipta |
| Teva Pharmaceuticals USA, INC. | $242.87 | 2019-2021 | |
| Amgen INC. | $214.99 | 2020-2025 | Repatha, Repatha, Uplizna |
| Ucb, INC. | $166.72 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $161.09 | 2019-2021 | |
| Lilly USA, LLC | $150.14 | 2022-2023 | Amyvid |
| Abbott Laboratories | $127.28 | 2025 | Proclaim |
| Allergan, INC. | $94.55 | 2019-2021 | |
| Lundbeck LLC | $91.26 | 2020-2025 | Vyepti |
| Alexion Pharmaceuticals, INC. | $82.59 | 2020 | |
| Biogen, INC. | $38.78 | 2023 | Avonex, Vumerity, Plegridy |
| Atricure, INC. | $25.77 | 2023 | |
| Glaxosmithkline, LLC. | $22.42 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $22.05 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.50 | 2024 | Lifevest |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $19.93 | 2023 | |
| Supernus Pharmaceuticals, INC. | $18.51 | 2019 | |
| Merck Sharp & Dohme LLC | $18.44 | 2023 | Verquvo, Belsomra |
| Biohaven Pharmaceutical Holding Company Ltd. | $17.65 | 2022 | |
| Argenx US, INC. | $13.65 | 2023 | Vyvgart |
| Adamas Pharmaceuticals, INC. | $13.58 | 2021 | |
| Pfizer INC. | $13.49 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinod Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.